Best Practices for Operationalizing Bispecific Antibody Therapy in Follicular Lymphoma

EP: 1.Introduction and Exploring the Financial Burden of Follicular Lymphoma

EP: 2.Optimizing First- and Second-Line Treatment Strategies in Follicular Lymphoma

EP: 3.Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy

EP: 4.Integrating Bispecific Antibodies and Evolving Strategies in Relapsed/Refractory Follicular Lymphoma

EP: 5.Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma

EP: 6.Targeted Therapies and Bispecific Antibodies in Second-Line Follicular Lymphoma

EP: 7.Epcoritamab Maintenance and Quality of Life Considerations in Follicular Lymphoma

EP: 8.Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma

EP: 9.Operational Challenges and Solutions for Implementing Bispecific Antibodies in Follicular Lymphoma

Now Viewing

EP: 10.Best Practices for Operationalizing Bispecific Antibody Therapy in Follicular Lymphoma

EP: 11.Optimizing Epcoritamab Dosing and Treatment Considerations in Second-Line Follicular Lymphoma

Successfully implementing bispecific antibody therapy for follicular lymphoma requires robust operational protocols and seamless care transitions. Best practices include developing standardized workflows for administration, monitoring, and toxicity management that are tailored to each health system’s resources. Key stakeholders—physicians, advanced practice providers, nurses, pharmacists, and administrative staff—play distinct but complementary roles, from patient selection and dosing to education and coordination of follow-up. Optimizing transitions of care between inpatient and outpatient settings is critical, particularly for managing adverse events like cytokine release syndrome or infusion reactions, ensuring continuity, and reducing readmissions. Operational hurdles such as staff training, scheduling complexity, and resource allocation must be proactively addressed through multidisciplinary collaboration and iterative process improvement. By integrating these strategies, health systems can safely expand the use of bispecific antibodies while enhancing efficiency, patient experience, and overall treatment outcomes.